CRS and HIPEC for Peritoneal Metastasis from Colorectal Cancer
Publisher
Springer Singapore
Reference14 articles.
1. Ihemelandu CU, Shen P, Stewart JH, Votanopoulos K, Levine EA. Management of peritoneal carcinomatosis from colorectal cancer. Semin Oncol. 2011 Aug;38(4):568–75.
2. Bhatt A, Goéré D. Cytoreductive surgery plus HIPEC for peritoneal metastases from colorectal Cancer. Indian J Surg Oncol. 2016 Jun;7(2):177.
3. Klaver CEL, Musters GD, Bemelman WA, Punt CJA, Verwaal VJ, Dijkgraaf MG, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer [Internet]. 2015 May 24 [cited 2018 Feb 7];15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492087/
4. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2008 Apr 20;26(12):2013–9.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335–42.